Compounds > bexarotene
Page last updated: 2024-08-25

bexarotene and tamoxifen

bexarotene has been researched along with tamoxifen in 11 studies

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (27.27)18.2507
2000's6 (54.55)29.6817
2010's2 (18.18)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Bischoff, ED; Gottardis, MM; Heyman, RA; Lamph, WW; Moon, TE1
Budel, V; Cahen, P; Chaboteaux, C; Darro, F; Decaestecker, C; Kiss, R; Leblond, B; Nogaret, JM; Pétein, M; Pourrias, B; Ramos, C; Schoofs, A; Vianna, A1
Bischoff, ED; Heyman, RA; Lamph, WW1
Cohen, MH; Flamm Honig, S; Hirschfeld, S; Ibrahim, A; Johnson, JR; O'Leary, JJ; Pazdur, R; White, RM; Williams, GA1
Baidas, S; Cohen, R; Demetri, GD; DeMichele, A; Dickler, M; Esteva, FJ; Glaspy, J; Hayes, DF; Hortobagyi, GN; Hutchins, L; Laufman, L; Osborne, CK; Tripathy, D; Winer, E; Yocum, RC1
Brose, HL; Gould, MN; Haag, JD; Hitt, AA; Hu, R; Kim, K; Lindstrom, MJ; Lubet, RA; Mau, B; Monson, DM; Steele, VE; Waller, JL; Watson, PA; Woditschka, S; Zheng, Y1
Crowell, JA; Cwik, MJ; Detrisac, CJ; Horn, TL; Kapetanovic, IM; Lubet, RA; McCormick, DL; Naylor, JM; Torres, KE1
Gould, MN; Haag, JD; Sullivan, R; Woditschka, S1
Boring, D; Grubbs, CJ; Juliana, MM; Lubet, RA; Ruppert, JM; Steele, VE1

Reviews

1 review(s) available for bexarotene and tamoxifen

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Trials

1 trial(s) available for bexarotene and tamoxifen

ArticleYear
Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Mar-15, Volume: 21, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Breast Neoplasms; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Estrogen Receptor Modulators; Female; Humans; Middle Aged; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Tamoxifen; Tetrahydronaphthalenes; Thyroid Hormones; Toremifene; Treatment Outcome

2003

Other Studies

9 other study(ies) available for bexarotene and tamoxifen

ArticleYear
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma.
    Cancer research, 1998, Feb-01, Volume: 58, Issue:3

    Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Cell Division; Drug Screening Assays, Antitumor; Drug Synergism; Female; Mammary Neoplasms, Experimental; Methylnitrosourea; Rats; Rats, Sprague-Dawley; Receptors, Retinoic Acid; Retinoid X Receptors; Tamoxifen; Tetrahydronaphthalenes; Transcription Factors

1998
Growth inhibition of human in vitro and mouse in vitro and in vivo mammary tumor models by retinoids in comparison with tamoxifen and the RU-486 anti-progestagen.
    Breast cancer research and treatment, 1998, Volume: 51, Issue:1

    Topics: Alitretinoin; Animals; Anticarcinogenic Agents; Apoptosis; Benzoates; Bexarotene; Breast Neoplasms; Cell Division; Disease Models, Animal; Female; Fenretinide; Hormone Antagonists; Humans; Mammary Neoplasms, Animal; Mice; Mice, Inbred C57BL; Mifepristone; Retinoids; Tamoxifen; Tetrahydronaphthalenes; Tretinoin; Tumor Cells, Cultured

1998
Effect of the retinoid X receptor-selective ligand LGD1069 on mammary carcinoma after tamoxifen failure.
    Journal of the National Cancer Institute, 1999, Dec-15, Volume: 91, Issue:24

    Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Carcinogens; Disease Progression; Female; Mammary Neoplasms, Experimental; Methylnitrosourea; Rats; Rats, Sprague-Dawley; Tamoxifen; Tetrahydronaphthalenes; Treatment Failure; Treatment Outcome

1999
Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene.
    The oncologist, 2001, Volume: 6, Issue:1

    Topics: Anastrozole; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Arsenic Trioxide; Arsenicals; Bexarotene; Breast Neoplasms; Drug Approval; Female; Humans; Leukemia, Promyelocytic, Acute; Lymphoma, T-Cell, Cutaneous; Nitriles; Oxides; Paclitaxel; Tamoxifen; Tetrahydronaphthalenes; Triazoles; United States; United States Food and Drug Administration

2001
Neu-induced retroviral rat mammary carcinogenesis: a novel chemoprevention model for both hormonally responsive and nonresponsive mammary carcinomas.
    Cancer research, 2006, Jul-01, Volume: 66, Issue:13

    Topics: Animals; Anticarcinogenic Agents; Bexarotene; Body Weight; Disease Models, Animal; Female; Genes, erbB-2; Genetic Vectors; Mammary Neoplasms, Experimental; Neoplasms, Hormone-Dependent; Nicotinic Acids; Rats; Rats, Inbred WF; Retroviridae; Tamoxifen; Tetrahydronaphthalenes

2006
Subchronic toxicity and toxicogenomic evaluation of tamoxifen citrate + bexarotene in female rats.
    Toxicological sciences : an official journal of the Society of Toxicology, 2007, Volume: 99, Issue:2

    Topics: Animals; Bexarotene; Dimerization; Dose-Response Relationship, Drug; Female; Gene Expression Profiling; Liver; Oligonucleotide Array Sequence Analysis; PPAR alpha; Rats; Rats, Sprague-Dawley; Receptors, Retinoic Acid; Retinoid X Receptors; Reverse Transcriptase Polymerase Chain Reaction; Tamoxifen; Tetrahydronaphthalenes; Toxicogenetics

2007
A short-term rat mammary carcinogenesis model for the prevention of hormonally responsive and nonresponsive in situ carcinomas.
    Cancer prevention research (Philadelphia, Pa.), 2009, Volume: 2, Issue:2

    Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Apoptosis; Bexarotene; Carcinoma in Situ; Celecoxib; Cell Proliferation; Cyclooxygenase Inhibitors; Disease Models, Animal; Female; Genes, erbB-2; Mammary Neoplasms, Experimental; Neoplasms, Hormone-Dependent; Pyrazoles; Rats; Rats, Inbred WF; Retroviridae; Sulfonamides; Tamoxifen; Tetrahydronaphthalenes; Time Factors

2009
Lack of efficacy of the statins atorvastatin and lovastatin in rodent mammary carcinogenesis.
    Cancer prevention research (Philadelphia, Pa.), 2009, Volume: 2, Issue:2

    Topics: Alkylating Agents; Animals; Anticarcinogenic Agents; Anticholesteremic Agents; Antineoplastic Agents, Hormonal; Apoptosis; Atorvastatin; Bexarotene; Cell Proliferation; Diet; Disease Models, Animal; Female; Genes, erbB-2; Heptanoic Acids; Lovastatin; Mammary Neoplasms, Experimental; Methylnitrosourea; Mice; Mice, Knockout; Mice, Transgenic; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Retinoid X Receptors; Tamoxifen; Tetrahydronaphthalenes; Treatment Outcome; Tumor Suppressor Protein p53

2009